Research
Premium Reports
Decision-grade industry intelligence for leadership teams and investors. Built from operator interviews and regulatory analysis that does not appear in analyst reports.
The State of Radiopharmaceuticals 2026
The definitive operating-reality assessment of the global radiopharmaceutical sector
Built from executive search mandate intelligence across 50+ radiopharma organisations. A working analysis of isotope supply-chain fragility, the alpha emitter transition, manufacturing scale-up constraints, NRC/FDA regulatory divergence, radiation-qualified talent scarcity, and capital reallocation across the industry.
Single-user PDF
Buy Individual LicenseKey Topics Covered
Isotope supply: Ac-225, Pb-212, At-211 production realities and bottlenecks
Manufacturing: alpha-ready facility requirements vs beta-legacy infrastructure
Regulatory: dual NRC/FDA oversight, international divergence, inspection readiness
Talent: the Authorised User bottleneck and radiation-qualified workforce scarcity
Capital: where institutional money is moving and why valuations face stress
Competitive landscape: vertical integrators vs platforms vs radiopharma CDMOs
Weaponised Capacity: The CDMO Report 2026
Why capacity no longer wins and where value is migrating in contract manufacturing
Dissects the structural reset across global contract manufacturing. Maps why post-pandemic CDMO capacity expansion has misfired and which contract manufacturers will compound value vs. quietly fail this cycle.
Key Topics Covered
The three wars of 2026: sovereignty, complexity, and talent
Ghost capacity: why announced capacity does not equal schedulable output
BIOSECURE Act and the fracturing of global pharmaceutical supply chains
PE-backed CDMOs: exit pressure, platform fatigue, and consolidation dynamics
Complexity premium: ADC, viral vector, and radiation-grade manufacturing
CDMO talent scarcity: where the qualified people are and are not